A Study to Evaluate Topical ATR04-484 for EGFRi-Associated Dermal Toxicity

NCT06830863 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

32

Enrollment

INDUSTRY

Sponsor class

Conditions

EGFR Inhibitor-associated Rash

Interventions

DRUG: ATR04-484
DRUG: Vehicle

Sponsor

Azitra Inc.

Collaborators

Prosoft Clinical